Dana-Farber Cancer Institute
This research is being done to test a program to assess and manage reversible cardiovascular (CV) risk factors in participants with prostate cancer starting androgen deprivation therapy (ADT), with the goal of integrating a standardized method into Dana-Farber Cancer Institute clinics for all such participants. The name of the intervention used in this research study is: CV Care (cardiovascular risk assessment and management program)
This research is being done to test a program to assess and manage reversible cardiovascular (CV) risk factors in participants with prostate cancer starting androgen deprivation therapy (ADT), with the goal of integrating a standardized method into Dana-Farber Cancer Institute clinics for all such participants. Study procedures including screening for eligibility, treatment visits, questionnaires and surveys, and blood and urine tests. Participation in this research study is expected to last about 6 months. It is expected that about 60-150 people will take part in this study. This study is…
Inclusion Criteria: * Participants must have a histologic diagnosis of prostate adenocarcinoma. Participants with any stage of prostate cancer are eligible, as long as treatment with at least 24 weeks of ADT is recommended by their treating physician. * Participants must have been prescribed a plan for treatment with at least 24 weeks of ADT, and can have received up to 12 weeks of ADT therapy. * Participants must be willing to participate in two CV CARE visits at weeks 12 and 24 after ADT initiation. * Participants must be willing to have their follow up visits for ADT management at DFCI Lon…
Comprised of two, in-clinic, counseling sessions with oncology nurse practitioner or physician assistant for education on cardiovascular disease (CVD) and cardiovascular risk factors as well as recommendations for management.
Arctuva estimate
Verify or correct the compensation shown for this listing.